Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Ewing sarcoma (EWS) is a rare bone and soft tissue cancer affecting adolescents and adults.
• Relapsed EWS lacks effective standard treatment, and recent trials failed to improve survival with more chemotherapy drugs.
• There is a critical need for novel therapeutic strategies to enhance remission durability in EWS.

Purpose of the Study:

• To investigate non-chemotherapy adjuvant drug candidates for combination therapy in EWS.
• To identify potential agents that can extend remission durability beyond standard chemotherapy.

Main Methods:

• In vitro efficacy assessment using anchorage-dependent and anchorage-independent growth assays.
• In vivo evaluation of drug candidates in EWS xenograft mouse models.
• Screening of three novel adjuvant drug candidates in combination with chemotherapy.

Main Results:

• Enoxacin and entinostat demonstrated the most significant efficacy as adjuvant therapies.
• Both drugs showed effectiveness in long-term in vitro and in vivo studies.
• Enoxacin, an FDA-approved antibiotic, and entinostat, an investigational agent, were identified as lead candidates.

Conclusions:

• Enoxacin and entinostat are effective adjuvant drug candidates for Ewing sarcoma.
• Enoxacin is proposed for further preclinical and clinical investigation due to its FDA approval and demonstrated efficacy.
• Adjuvant therapy with enoxacin may offer a new strategy to improve outcomes for EWS patients.